These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 21453265)

  • 21. Comparative assessment of lipid based nano-carrier systems for dendritic cell based targeting of tumor re-initiating cells in gynecological cancers.
    Bhargava A; Mishra DK; Jain SK; Srivastava RK; Lohiya NK; Mishra PK
    Mol Immunol; 2016 Nov; 79():98-112. PubMed ID: 27764711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendritic cells from bench to bedside and back.
    Adema GJ
    Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
    Bodey B; Siegel SE; Kaiser HE
    In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mRNA-based dendritic cell vaccines.
    Benteyn D; Heirman C; Bonehill A; Thielemans K; Breckpot K
    Expert Rev Vaccines; 2015 Feb; 14(2):161-76. PubMed ID: 25196947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine.
    Foley R; Tozer R; Wan Y
    Transfus Med Rev; 2001 Oct; 15(4):292-304. PubMed ID: 11668436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells.
    Dionisi M; De Archangelis C; Battisti F; Rahimi Koshkaki H; Belleudi F; Zizzari IG; Ruscito I; Albano C; Di Filippo A; Torrisi MR; Benedetti Panici P; Napoletano C; Nuti M; Rughetti A
    Front Immunol; 2018; 9():2481. PubMed ID: 30455687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
    H Yi D; Appel S
    Scand J Immunol; 2013 Aug; 78(2):167-71. PubMed ID: 23672402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting dendritic cells with antigen-containing liposomes: antitumour immunity.
    Altin JG; van Broekhoven CL; Parish CR
    Expert Opin Biol Ther; 2004 Nov; 4(11):1735-47. PubMed ID: 15500402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy.
    Shimizu K; Kuriyama H; Kjaergaard J; Lee W; Tanaka H; Shu S
    J Immunother; 2004; 27(4):265-72. PubMed ID: 15235387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells.
    Le Moignic A; Malard V; Benvegnu T; Lemiègre L; Berchel M; Jaffrès PA; Baillou C; Delost M; Macedo R; Rochefort J; Lescaille G; Pichon C; Lemoine FM; Midoux P; Mateo V
    J Control Release; 2018 May; 278():110-121. PubMed ID: 29630987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
    Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
    Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cell gene therapy.
    Onaitis M; Kalady MF; Pruitt S; Tyler DS
    Surg Oncol Clin N Am; 2002 Jul; 11(3):645-60. PubMed ID: 12487060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic dendritic cell-based cancer vaccines: the state of the art.
    Strioga MM; Felzmann T; Powell DJ; Ostapenko V; Dobrovolskiene NT; Matuskova M; Michalek J; Schijns VE
    Crit Rev Immunol; 2013; 33(6):489-547. PubMed ID: 24266347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic cell-based immunotherapy.
    Osada T; Clay TM; Woo CY; Morse MA; Lyerly HK
    Int Rev Immunol; 2006; 25(5-6):377-413. PubMed ID: 17169781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating dendritic cells as an in vitro screening tool for immunotherapeutic formulations.
    El-Murr T; Patel A; Sedlak C; D'Souza-Lobo B
    J Immunol Methods; 2018 Aug; 459():55-62. PubMed ID: 29800576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic cell-based nanovaccines for cancer immunotherapy.
    Paulis LE; Mandal S; Kreutz M; Figdor CG
    Curr Opin Immunol; 2013 Jun; 25(3):389-95. PubMed ID: 23571027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
    Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
    Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.